Sheppard Mullin Richter & Hampton LLP
Syk inhibitors
The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein X1, X2, X3, R2, R3, R4, R5, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk. 
Gilead Sciences, Inc.
C C A A C A A C A A A A C C A C A A C C A C C A C C A A A C
C07D C07D A61P A61P C07D A61P A61P C07D A61P A61P A61P A61P C07D C07D A61P C07D A61P A61P C07D C07D A61P C07D C07D A61P C07D C07D A61P A61P A61P C07D
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Jiayao Kirk L. Sheila Jayaraman Chandrasekar Jeffrey E. Seung H. Zhimin Jennifer R. Gregory Nicholas Juan A. Julie Aaron C. Michael Scott E. Jianjun Jeff Ashley A. Zheng-Yu Peter A. Jin-Ming Zhongdong Kevin S. John O. Darryl Adam J. Scott A. Hyung-jung William J.
Li Stevens Zipfel Chandrasekhar Venkataramani Kropf Lee Du Lo Notte Mai Guerrero Farand Schmitt Sangi Lazerwith Xu Zablocki Katana Yang Blomgren Xiong Zhao Currie Link Kato Schrier Mitchell Pyun Watkins